GSK logo linking to the homepage Home > Innovation > Therapeutic areas > Oncology Oncology Our expertise in oncology allows us to bring groundbreaking cancer therapies to the patients who need it most. Strategic approach Blood cancers, gynaecologic cancers and other solid tumours Imm Immuno-oncology science image2SK logo linking to the homepage difference: 1. Immuno-oncology to harness the body's immune system to fight cancer 2. Synthetic lethality to combine two genetic mechanisms to destroy cancerous cells 3. Tumour cell targeting to identify cancer cell-specific traits We have accelerated research areas including synthetic lethality and next generation immuno-oncology agents, drawing on our own expertise in human genetics and the science of the immune system, and that of our partners. Meet Laura: surviving cancer and helping others Meet Laura View on YouTube Innovating together Our disease areas of focus2SK logo linking to the homepage patients with multiple myeloma. Multiple myeloma is the third most common blood cancer worldwide — more than 175,000 people are diagnosed every year. Currently, there are limited treatment options for patients with multiple myeloma after they progress through several stages of disease. Thus, our goal is to offer more tools for patients across all lines of therapy. Gynaecologic cancers are some of the most common cancers affecting women. In 2020, nearly 14 million women around the world were diagnosed with a gynaecologic cancer. We are focused on developing new medicines across a range of different modalities both as monotherapy and in combination for a variety of cancers, including ovarian and endometrial. We are investigating new treatment options for patients with advanced non-small cell lung cancer by combining our own therapies with standard care treatment, in the hope of discovering additional therapeutic options for patients with this challenging diagnosis. We are also exploring the use of one of our therapies as an early-stage treatment for breast cancer, using personalised technology that may enable for earlier detection of tumour cells. This could lead to further personalised treatment, potentially slowing or stopping the cancers progress, especially for women at higher risk of recurrence. ~ AS BEHIND THE SCIENCE Tania Small. MD — our VP and Global Medical Oncology Franchica Hand — dienticcar nue annmach tn BRP ineliidineJ3SK logo linking to the homepage Rega we aruce avout gyngecoogic cancers Exploring science and other collaborations Across our R&D in oncology, we invest in new technologies and partnerships to push the boundaries of cancer research. One of the most important areas is immuno-oncology. Additionally, functional genomics helps us identify new treatment targets in synthetic lethality, an approach to cancer treatment that targets only genetic mutations in cancer cells, not healthy cells. Continuing advances in immuno-oncology Immuno-oncology is a fast-developing area. However, the search for new targets is important as currently less than 30% of patients respond to certain immuno-oncology treatments. Through our work, we are aiming to help the immune system recognise and kill cancer cells more effectively. We're studying how combinations of different therapies can enhance anti-tumour activity utilising the CD226 axis that is expressed on the surface of T-cells and natural killer cells. Our collaborations with iTeos and Surface Oncology have allowed us to grow and develop our pipeline to potentially help more patients through ‘muno-oncology combination therapy.2SK logo linking to the homepage BEHIND THE SCIENCE Learn more about how the next generation of immuno- oncology could help us get ahead of cancer Read article about immuno-oncology, Exploring the potential of functional genomics in synthetic lethality Our work on functional genomics has identified more than 10 target research candidates in the field of synthetic lethality. Collaborating with IDEAYA Biosciences, an2SK logo linking to the homepage BEHIND THE SCIENCE Learn more about synthetic lethality treatments = 7 Read the article about Synthetic Lethality Continue to Immunology This is our global website, intended for visitors seeking information on GSK's worldwide business, Our market sites can be reached by visiting ‘our location selector.2SK logo linking to the homepage Modem Slavery Act statement 2022 (PDF -1897KB)